Privium Fund Management B.V. Buys 46,035 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Privium Fund Management B.V. boosted its stake in Autolus Therapeutics plc (NASDAQ:AUTL) by 24.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 231,674 shares of the company’s stock after acquiring an additional 46,035 shares during the quarter. Privium Fund Management B.V.’s holdings in Autolus Therapeutics were worth $544,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Autolus Therapeutics in the 4th quarter valued at about $611,000. Wellington Management Group LLP raised its position in Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares during the last quarter. FMR LLC lifted its stake in Autolus Therapeutics by 44.6% in the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after acquiring an additional 5,478,706 shares in the last quarter. Erste Asset Management GmbH acquired a new position in Autolus Therapeutics during the 3rd quarter worth approximately $708,000. Finally, JPMorgan Chase & Co. boosted its position in Autolus Therapeutics by 145.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock worth $4,663,000 after acquiring an additional 761,008 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, January 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Autolus Therapeutics presently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Performance

NASDAQ:AUTL opened at $1.79 on Wednesday. Autolus Therapeutics plc has a 52-week low of $1.68 and a 52-week high of $6.63. The company has a market cap of $476.31 million, a P/E ratio of -1.48 and a beta of 2.07. The stock’s 50-day simple moving average is $2.06 and its 200 day simple moving average is $2.95.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.